Stephen Leeb

Stephen Leeb, Ph.D. is the Chief Investment Strategist of The Complete Investor and Real World Investing.

Dr. Leeb’s books have been notable for predicting the secular bull market that started in the 1980s (Getting in on the Ground Floor, Putnam, 1986); the tech stock crash and rise of real assets, including oil and gold (Defying the Market: Profiting in the Turbulent Post-Technology Market Boom, McGraw-Hill, 1999); and the surge in oil prices (The Oil Factor: Protect Yourself and Profit from the Coming Energy Crisis, Warner Books, 2004). His national bestseller, The Coming Economic Collapse: How You Can Thrive When Oil Costs $200 a Barrel (Warner Books, 2006), co-authored with Glen Strathy, outlined the biggest challenges facing the US economy, and accurately predicted the 2008 sub prime mortgage crisis as well as the vicious subsequent economic cycle requiring massive infusions of government stimulus, near zero interest rates and much higher federal debt levels. Game Over: How You Can Prosper in a Shattered Economy (Business Plus, 2009) predicted a permanent peak in global commodity production. Dr. Leeb’s eighth and latest book, Red Alert (Hachette, 2011), outlined China’s growing prosperity and the ways in which its demands on increasingly scarce resources threaten the American way of life.

Among his many speaking engagements, he has been the keynote speaker at both a JPMorgan Chase energy conference and a Royal Bank of Canada commodities conference.

Dr. Leeb received his bachelor’s degree in Economics from the University of Pennsylvania’s Wharton School of Business. He then earned his master’s degree in Mathematics and Ph.D. in Psychology from the University of Illinois in just three years, an academic record that stands to date. He is frequently quoted in the financial media, including Investors Business Daily, USA Today, Business Week, The New York Times, NPR and The Wall Street Journal. In addition, Dr. Leeb is a regular guest on Fox News, Bloomberg, CNN and Neil Cavuto.

Analyst Articles

Gaining appeal as the yuan becomes a reserve currency By Stephen Leeb  Before the end of October, China’s currency should be officially installed as a component of the SDR currency units issued and maintained by the IMF. This will make the yuan one of five currencies—the other four are the… Read More

3 beaten-down stocks we still think will triumph By Stephen Leeb Of the 40 stocks in Growth Portfolio, there are five that, like wayward children, keep us up at night wondering how they’ll end up. We discussed two of them, Bristol-Myers (BMY) and Gilead (GILD), last issue, and we continue… Read More

The miners lead the charge By Stephen Leeb The year’s biggest investment story—spectacular gains by gold and silver mining stocks—has gotten precious little ink in the financial press. The six-month bull surge in the miners has far outpaced even the substantial rise in the underlying metals. In fact, it nearly… Read More

Bristol-Myers and Gilead are down but far from out By Stephen Leeb Over the past month, two of Growth Portfolio’s drug recommendations—Bristol-Myers-Squibb (BMY) (also in Income/Value) and Gilead Sciences (GILD)—suffered disappointments that led investors to hit them hard. But in both cases we think the reaction was more severe than… Read More

We Highlight Four Defense and Cybersecurity Stalwarts By Stephen Leeb Ph.D. One year ago, when I became editor of Leeb’s Real World Investing (RWI), I defined its mission as keeping you protected against the biggest dangers posed by our very dangerous world. I outlined the critical areas… Read More

Big caps that are anything but stodgy By Stephen Leeb Sometimes it pays not to overlook the obvious. The venerable Dow Jones Industrial Average may seem simply too familiar to offer much of interest. But in a world where finding the Holy Grail of growth plus safety is becoming ever… Read More

Maintaining a uniquely successful management methodology By Stephen Leeb This issue we are selling one stock, Visa (V), and buying another, Fortive (FTV), a company that recently was spun off from our existing recommendation Danaher (DHR). First, our sale of Visa, which we are making for several reasons, starting with… Read More

By Stephen Leeb Ph.D. We see Brexit as proof positive that the austerity so widely imposed in Europe in the recent past was precisely the wrong medicine. Worse, it was treatment that risked killing the patient. So however shocking or out of the blue the Brexit vote may have seemed,… Read More